0000000000337382

AUTHOR

Enrico Agabiti-rosei

showing 13 related works from this author

Riskard 2005. New tools for prediction of cardiovascular disease risk derived from Italian population studies.

2005

Abstract Background and aim The need to update tools for the estimate of cardiovascular risk prompted the “Gruppo di Ricerca per la Stima del Rischio Cardiovascolare in Italia” to produce a new chart and new software called Riskard 2005. Methods and results Data from 9 population studies in 8 Italian regions, for a grand total of 17,153 subjects (12,045 men and 5,108 women) aged 35–74 and for a total exposure of about 194,000 person/years were available. A chart for the estimate of cardiovascular risk (major coronary, cerebrovascular and peripheral artery disease events) in 10 years was produced for men and women aged 45–74 free from cardiovascular diseases. Risk factors employed in the est…

AdultMaleRiskmedicine.medical_specialtyEndocrinology Diabetes and MetabolismPopulationMedicine (miscellaneous)Risk AssessmentDiabetes ComplicationsSex FactorsPredictive Value of TestsRisk FactorsSoftware DesignPrevalenceMedicineHumansRisk factoreducationAgededucation.field_of_studyNutrition and DieteticsFramingham Risk Scorebusiness.industrySmokingAbsolute risk reductionAge FactorsMiddle AgedSurgeryRisk EstimateCholesterolItalyCardiovascular DiseasesRelative riskHypertensionFemaleCardiology and Cardiovascular MedicinebusinessRisk assessmentBody mass indexAlgorithmsDemographyFollow-Up StudiesNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence.

2014

BACKGROUND AND OBJECTIVES:: It is well established by a large number of randomized controlled trials that lowering blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) by drugs are powerful means to reduce stroke incidence, but the optimal BP and LDL-C levels to be achieved are largely uncertain. Concerning BP targets, two hypotheses are being confronted: first, the lower the BP, the better the treatment outcome, and second, the hypothesis that too low BP values are accompanied by a lower benefit and even higher risk. It is also unknown whether BP lowering and LDL-C lowering have additive beneficial effects for the primary and secondary prevention of stroke, and whether these…

Malemedicine.medical_specialtyPhysiologyHypercholesterolemiaLow density lipoprotein cholesterolBlood Pressurelaw.inventionCognitionRandomized controlled triallawRecurrenceInternal medicineblood pressure cognitive decline low-density lipoprotein cholesterol primary prevention secondary prevention strokeInternal MedicineSecondary PreventionMedicineHumansCognitive declineStrokeBeneficial effectsRandomized Controlled Trials as TopicSecondary preventionbusiness.industryMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARECholesterol LDLmedicine.diseasePrimary PreventionStrokeBlood pressureCholesterolCardiologyPhysical therapylipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessStroke incidenceCognition Disordersblood pressure; cognitive decline; low-density lipoprotein cholesterol; primary prevention; secondary prevention; strokeJournal of hypertension
researchProduct

Non-invasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients

2017

International audience; Arterial hypertension (HTN) accounts for the largest amount of attributable cardiovascular (CV) mortality worldwide, and risk stratification in hypertensive patients is of crucial importance to manage treatment and prevent adverse events. Asymptomatic involvement of different organs in patients affected by HTN represents an independent determinant of CV risk and the identification of target organ damage (TOD) is recommended to further reclassify patients' risk. Non-invasive CV imaging is progressively being used and continues to provide new technological opportunities to TOD evaluation at early stage. The aim of this article is to provide the community of cardiology …

cardiovascular riskmedicine.medical_specialtyarterial hypertension[SDV]Life Sciences [q-bio]Population030204 cardiovascular system & hematologyAsymptomatic03 medical and health sciences0302 clinical medicineInternal medicinetarget organ damageMedicineRadiology Nuclear Medicine and imagingIn patient030212 general & internal medicineAdverse effecteducationnon-invasive cardiovascular imagingSubclinical infectioneducation.field_of_studybusiness.industryNon invasiveGeneral MedicineTarget organ damage3. Good healthRisk stratificationCardiologyprognosismedicine.symptomCardiology and Cardiovascular Medicinebusiness
researchProduct

Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive tre…

2016

medicine.medical_specialtyPhysiologybusiness.industry030204 cardiovascular system & hematologymedicine.disease03 medical and health sciences0302 clinical medicineBlood pressureSprintShot (pellet)Internal MedicinePhysical therapyMedicine030212 general & internal medicineCardiology and Cardiovascular MedicinebusinessStrokeJournal of hypertension
researchProduct

Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient : design of the Euro…

2014

BACKGROUND AND OBJECTIVES:: The SBP values to be achieved by antihypertensive therapy in order to maximize reduction of cardiovascular outcomes are unknown; neither is it clear whether in patients with a previous cardiovascular event, the optimal values are lower than in the low-to-moderate risk hypertensive patients, or a more cautious blood pressure (BP) reduction should be obtained. Because of the uncertainty whether 'the lower the better' or the 'J-curve' hypothesis is correct, the European Society of Hypertension and the Chinese Hypertension League have promoted a randomized trial comparing antihypertensive treatment strategies aiming at three different SBP targets in hypertensive pati…

Malemedicine.medical_specialtyChinaPhysiologyBlood Pressurelaw.inventionchemistry.chemical_compoundCognitionRandomized controlled triallawRecurrenceInternal medicineInternal MedicinemedicineSecondary Preventionblood pressure; cognitive decline; low-density lipoprotein cholesterol; randomized controlled trial; secondary prevention; strokeDementiaHumansProspective StudiesCognitive declineProspective cohort studyStrokeAntihypertensive AgentsAgedLdl cholesterolCholesterolbusiness.industryBlood Pressure DeterminationCholesterol LDLlipoprotein cholesterol randomized controlled trial secondary prevention strokeMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREmedicine.diseaseblood pressure cognitive decline low-densityEuropeStrokeBlood pressurechemistryIschemic Attack TransientHypertensionPhysical therapyCardiologyDementiaHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessCognition Disorders
researchProduct

Agreement within Europe about antihypertensive treatment and education – results from the European Society of Hypertension questionnaire

2010

medicine.medical_specialtyPediatricsPhysiologybusiness.industrymedia_common.quotation_subjectMEDLINEAgreementEuropeFamily medicineHypertensionPractice Guidelines as TopicInternal MedicinemedicineHumansMulticenter Studies as TopicCardiology and Cardiovascular MedicinebusinessAntihypertensive Agentsmedia_commonJournal of Hypertension
researchProduct

Nutraceuticals and blood pressure control: A European Society of Hypertension position document

2020

: High-normal blood pressure (BP) is associated with an increased risk of cardiovascular disease, however the cost-benefit ratio of the use of antihypertensive treatment in these patients is not yet clear. Some dietary components and natural products seems to be able to significantly lower BP without significant side effects. The aim of this position document is to highlight which of these products have the most clinically significant antihypertensive action and wheter they could be suggested to patients with high-normal BP. Among foods, beetroot juice has the most covincing evidence of antihypertensive effect. Antioxidant-rich beverages (teas, coffee) could be considered. Among nutrients, …

Blood pressure controlPhysiologyPhysiologyDisease030204 cardiovascular system & hematologyResveratrolBeetroot JuiceAntioxidantsMelatoninBeveragesdietary supplements03 medical and health scienceschemistry.chemical_compoundPrehypertensionblood pressure; consensus; dietary supplements; food; nutraceuticals0302 clinical medicineNutraceuticalInternal MedicinemedicineHumansMagnesium030212 general & internal medicineAntihypertensive AgentsMelatoninBlood pressure consensus dietary supplements food nutraceuticalsnutraceuticalsVitamin Cbusiness.industryfoodblood pressureBlood pressurechemistryconsensusHypertensionPotassiumCardiology and Cardiovascular Medicinebusinessmedicine.drug
researchProduct

Expertise

2017

Several sets of guidelines have been published recently and more are in the works. The very recent American College of Physicians/American Academy of Family Practitioners guidelines were put together by a set of authors and consultants without any expertise in the topic under discussion, that is, hypertension. Although we are not maintaining that all guidelines should be written exclusively by experts, complete lack of expertise among guideline authors is not acceptable. ispartof: Journal Of Hypertension vol:35 issue:8 pages:1564-1566 ispartof: location:Netherlands status: published

Pediatricsmedicine.medical_specialtyhypertensionPhysiologySine qua nonAlternative medicineMEDLINE030204 cardiovascular system & hematology1102 Cardiovascular Medicine And Haematology03 medical and health sciencesProfessional Competence0302 clinical medicineInternal MedicinemedicineHumansBLOOD-PRESSURE TARGETSguidelines030212 general & internal medicineSet (psychology)Societies MedicalMETAANALYSISANGIO-EDEMAOLDERMedical educationScience & Technologybusiness.industry1103 Clinical SciencesAGED 60 YEARSGuidelineProfessional competence3. Good healthPeripheral Vascular DiseaseCardiovascular System & HematologyPractice Guidelines as TopicCardiovascular System & CardiologyexpertiseINHIBITORSCardiology and Cardiovascular MedicinebusinessLife Sciences & BiomedicineguidelineANGIO-EDEMAJournal of Hypertension
researchProduct

MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled tr…

2018

Introduction Masked uncontrolled hypertension (MUCH) carries an increased risk of cardiovascular (CV) complications and can be identified through combined use of office (O) and ambulatory (A) blood pressure (BP) monitoring (M) in treated patients. However, it is still debated whether the information carried by ABPM should be considered for MUCH management. Aim of the MASked-unconTrolled hypERtension management based on OBP or on ambulatory blood pressure measurement (MASTER) Study is to assess the impact on outcome of MUCH management based on OBPM or ABPM. Methods and analysis MASTER is a 4-year prospective, randomised, open-label, blinded-endpoint investigation. A total of 1240 treated hyp…

HYPERTENSION MANAGEMENTHipertensión.1302masked uncontrolled hypertensionEnfermedades cardiovasculares - Pacientes - Factores de riesgo.office blood pressureMASKED UNCONTROLLED HYPERTENSIONMedicina ClínicaCardiovascular Medicine030204 cardiovascular system & hematologyAMBULATORY BLOOD PRESSURE MONITORINGlaw.invention0302 clinical medicineClinical trialsRandomized controlled triallawBlood Pressure MonitoringMasked Hypertension//purl.org/becyt/ford/3.2 [https]ProtocolMulticenter Studies as Topic1506030212 general & internal medicineCardiovascular system - Diseases - Patients - Risk factors.Blood pressure.OFFICE BLOOD PRESSURERandomized Controlled Trials as TopicSistemas Cardíaco y CardiovascularGeneral MedicineBlood Pressure Monitoring Ambulatory3. Good healthCor MalaltiesEchocardiographyAmbulatoryHypertensionBlood pressure//purl.org/becyt/ford/3 [https]Hipertensióambulatory blood pressure monitoring; hypertension; hypertension management; masked uncontrolled hypertension; office blood pressure; treated hypertensive patientsTREATED HYPERTENSIVE PATIENTS1683medicine.medical_specialtyAmbulatory blood pressureCIENCIAS MÉDICAS Y DE LA SALUDhypertensionHeart Ventriclestreated hypertensive patientPressió sanguínia03 medical and health sciencesAmbulatoryHypertension.medicineAlbuminuriaHumansAntihypertensive AgentsProtocol (science)business.industryConsolidated Standards of Reporting Trialsambulatory blood pressure monitoring; hypertension; hypertension management; masked uncontrolled hypertension; office blood pressure; treated hypertensive patients; Albuminuria; Antihypertensive Agents; Echocardiography; Heart Ventricles; Humans; Masked Hypertension; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Blood Pressure Monitoring Ambulatorytreated hypertensive patientsambulatory blood pressure monitoringBlood pressurePresión sanguínea.Good clinical practiceEmergency medicinebusinessDeclaration of Helsinkihypertension managementAssaigs clínicsBMJ Open
researchProduct

Noninvasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: a consensus article from the European Ass…

2017

International audience; : Arterial hypertension accounts for the largest amount of attributable cardiovascular mortality worldwide, and risk stratification in hypertensive patients is of crucial importance to manage treatment and prevent adverse events. Asymptomatic involvement of different organs in patients affected by hypertension represents an independent determinant of cardiovascular risk, and the identification of target organ damage is recommended to further reclassify patients' risk. Noninvasive cardiovascular imaging is progressively being used and continues to provide new technological opportunities to target organ damage evaluation at early stage. The aim of this article is to pr…

cardiovascular riskRiskarterial hypertensionmedicine.medical_specialtyNoninvasive imagingPhysiologyPopulation030204 cardiovascular system & hematologyAsymptomatic03 medical and health sciences0302 clinical medicinetarget organ damageInternal medicineInternal MedicineHumansMedicineIn patient030212 general & internal medicineAdverse effectIntensive care medicineeducationSocieties MedicalCardiovascular mortalitySubclinical infectionCardiac Imaging Techniqueeducation.field_of_studybusiness.industrynoninvasive cardiovascular imagingTarget organ damage3. Good healthCardiac Imaging TechniquesHypertensionPractice Guidelines as TopicCardiology[SDV.IB]Life Sciences [q-bio]/Bioengineeringmedicine.symptomCardiology and Cardiovascular MedicinebusinessprognosiHuman
researchProduct

Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document

2009

Abbreviations ACE: angiotensin-converting enzyme; BP: blood pressure; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; ESC: European Society of Cardiology; ESH: European Society of Hypertension; ET: endothelin; IMT: carotid intima-media thickness; JNC: Joint National Commit

medicine.medical_specialtymanagement arterial hypertensionPhysiologyupdateRenal functionBlood PressureInternal medicinemedicineInternal MedicineHumanscardiovascular diseasesAntihypertensive AgentsTask forcebusiness.industryHypertension GuidelineHypertension managementGeneral MedicineEuropeOrgan damageBlood pressureHypertensionPractice Guidelines as Topiccardiovascular systemCardiologyMED/09 - MEDICINA INTERNAbusinessEndothelin receptorCardiology and Cardiovascular Medicine
researchProduct

Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease

2020

During the last century, there has been an increasing prevalence of hyperuricaemia noted in many populations. While uric acid is usually discussed in the context of gout, hyperuricaemia is also associated with hypertension, chronic kidney disease, hypertriglyceridaemia, obesity, atherosclerotic heart disease, metabolic syndrome, and type 2 diabetes. Here we review the connection between hyperuricaemia and cardiovascular, kidney and metabolic diseases. Contrary to the popular view that uric acid is an inert metabolite of purine metabolism, recent studies suggest serum uric acid may have a variety of pro-inflammatory, pro-oxidative and vasoconstrictive actions that may contribute to cardiomet…

medicine.medical_specialtyGoutHeart diseaseAllopurinolAllopurinolHyperuricemiaType 2 diabetes030204 cardiovascular system & hematologyurologic and male genital diseasesCoronary artery disease03 medical and health scienceschemistry.chemical_compoundFebuxostat0302 clinical medicineInternal medicineInternal MedicinemedicineHumans030212 general & internal medicineMetabolic SyndromeType 2 diabetes.business.industrynutritional and metabolic diseasesmedicine.diseaseUric AcidGoutDiabetes Mellitus Type 2chemistryHypertensionCardiologyUric acidMetabolic syndromebusinessHyperuricaemiaKidney diseasemedicine.drugEuropean Journal of Internal Medicine
researchProduct

2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents.

2016

Increasing prevalence of hypertension (HTN) in children and adolescents has become a significant public health issue driving a considerable amount of research. Aspects discussed in this document include advances in the definition of HTN in 16 year or older, clinical significance of isolated systolic HTN in youth, the importance of out of office and central blood pressure measurement, new risk factors for HTN, methods to assess vascular phenotypes, clustering of cardiovascular risk factors and treatment strategies among others. The recommendations of the present document synthesize a considerable amount of scientific data and clinical experience and represent the best clinical wisdom upon wh…

Gerontologymedicine.medical_specialtyAdolescentPhysiologyCardiovascular risk factorsPublic policyBlood PressureDiseaseComorbidity030204 cardiovascular system & hematologyKlinikai orvostudományokEuropeanManagement of high blood pressure03 medical and health sciences0302 clinical medicineCentral blood pressureRisk Factors030225 pediatricsmedicineInternal MedicinePrevalenceHumansClinical significancecardiovascular diseasesIntensive care medicineChildChildrenSociety of hypertensionCentral blood pressureAntihypertensive AgentsOut of office blood pressurebusiness.industryPublic healthRisk FactorBlood Pressure DeterminationOrvostudományokRecommendationmedicine.diseaseComorbidity3. Good healthAntihypertensive AgentBlood pressureHypertensionbusinessCardiology and Cardiovascular MedicineHumanJournal of hypertension
researchProduct